Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $143.70, down 0.53% on the day, which values the company at $354.24B. Price as of 17 Nov 2026, 17:33 UTC, from Yahoo Finance.

Key facts

Share price
$143.70−0.53% today
Market value
$354.24B
P/E ratio
145.1×last 12 months
Forward P/E
16.0×
Dividend yield
2.33%
Funk Score
59/100
Against its own history
Well above its usual priceusual price $95.05
200-week average
$110.0131% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Merck & Co., Inc. in more detail

MRK trades at 145.1× its last twelve months' earnings, 16.0× next year's expected earnings, 5.3× sales. Measured against its own history, the price is 51% above what its usual multiples would imply ($95.05) — well above its usual price. It sits 31% above its 200-week average of $110.01.

Over the last five fiscal years Merck & Co., Inc. has compounded revenue 9.4% a year, earnings per share 21.2% a year, free cash flow 16.2% a year. Its Funk Score is 59 out of 100 (financial strength 6.5, profitability 9.0, growth 7.1, value 1.1, each out of 10).

In its favour: Altman Z in the safe zone; Five straight years of revenue growth. Worth checking: Debt is growing faster than cash flow.

23 of the superinvestors tracked here hold MRK, including Bill Smead (7.1% of the portfolio), Thomas Kahn (4.9% of the portfolio), Bill Nygren (2.1% of the portfolio).

Superinvestors holding MRK

23 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:MRK vs UNH (Merck & Co., Inc. vs UnitedHealth Group)MRK vs NVS (Merck & Co., Inc. vs Novartis)MRK vs ABBV (Merck & Co., Inc. vs AbbVie)MRK vs AZN (Merck & Co., Inc. vs AstraZeneca)MRK vs JNJ (Merck & Co., Inc. vs Johnson & Johnson)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Merck & Co., Inc. (MRK): questions and answers

What is MRK's P/E ratio?

Merck & Co., Inc. trades at 145.1× its last twelve months' earnings and 16.0× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 6.5× to 128.7×, with a median of 21.6×.

What is MRK's PEG ratio?

Merck & Co., Inc.'s PEG ratio is 3.58 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Merck & Co., Inc.'s market cap?

Merck & Co., Inc. is valued at $354.24B at a share price of $143.70.

Is MRK overvalued or undervalued?

Against its own history, MRK is well above its usual price: the price is 51% above the $95.05 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is MRK above its 200-week moving average?

Yes. MRK is 30.6% above its 200-week average of $110.01. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Merck & Co., Inc. growing?

Over the last five fiscal years Merck & Co., Inc.'s revenue grew 9.4% a year and its earnings per share 21.2% a year; over ten years revenue grew 5.1% a year.

Cite this page

Funkfolio, “Merck & Co., Inc. (MRK) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MRK

Underlying data: Yahoo Finance; company filings with the SEC.